News desk
GLP-1 and Tirzepatide News
Regulatory and clinical developments, reported from the original announcement, with the event date kept separate from the publication date.
This desk covers FDA and regulatory action, clinical trial developments, manufacturer updates, pricing and access changes, pharmacy recalls and warning letters, and telehealth policy. Every item links its primary source and labels the evidence type. No stories have been published in this build.
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week
Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.
GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%
Current use has nearly quadrupled in two years. Over the same period national obesity prevalence declined from its 2022 peak.
Sandoz and Amneal File for Generic Tirzepatide — But Lilly's Patents Run to 2036
An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.
Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrollees
For the first time Medicare covers GLP-1s for weight loss — through a demonstration programme that expires at the end of 2027 with no confirmed successor.
A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond — Forming a Molecule Not in the Approved Drug
Additives used to differentiate compounded products from their approved counterparts are largely untested, and at least one interacts.
REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Loss
The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.
ACCESS II: A Second Oral Small-Molecule GLP-1 Posts 16.3% Placebo-Adjusted Weight Loss
Structure Therapeutics reports phase 2 results with no fasting window required — a direct challenge to oral semaglutide's administration burden.
Comment Period on the GLP-1 Bulks Proposal Extended to 30 July
FDA granted a 60-day extension after a request for more time. The window now closes days from publication, with no final determination in sight.
ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7%
The first strong signal that the composition of GLP-1 weight loss is pharmacologically modifiable — with a large gap still open on function.
ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain — and Tirzepatide's Extra Weight Loss Did Not Add More
Meaningful WOMAC reduction and less analgesic use, with an asymmetry that raises a question about mechanism.
FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claims
The June letters continue a pattern running back to September 2025, and the target is consistent: what providers say their product is.
The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Months
An uptake rate suggesting the oral route addressed a real barrier rather than offering a marginal alternative.
STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatide
A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure — if tolerability holds.
SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat
A 76-week phase 3 readout measuring where fat is lost, not only how much — which is the more clinically informative question.
SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabetes
A 9,647-patient outcomes trial reporting a 14% reduction in MACE and 22% in heart failure events — a hard-endpoint result in a field dominated by surrogate measures.
EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progression
A 3,808-patient, two-year programme returned a null result — and null results in this field deserve more coverage than they get.
CMS Delays the BALANCE Model Indefinitely and Extends the GLP-1 Bridge Instead
The programme meant to succeed the Bridge has been postponed without a new date, leaving temporary access with nothing confirmed behind it.
FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
The agency found no clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalised, it closes the last pathway for compounding at scale.
FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss
A once-daily pill with no food or water restrictions, available from $149 a month self-pay — and the lowest mean weight reduction of any approved option.
A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threat
The episode is widely cited as the point at which FDA enforcement shifted focus from compounders to the platforms marketing them.
FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products
The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.
TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times
A direct-to-consumer channel advertising semaglutide tablets from $149 and tirzepatide injections from $299, against list prices above $1,000.
Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Management
The first GLP-1 approved for a sleep disorder, following the SURMOUNT-OSA programme — and a coverage implication for patients whose plans exclude weight management.
FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management
The first oral GLP-1 approved for weight loss, with cardiovascular risk reduction on the label and results close to the injectable.
NovoCare Cuts Wegovy Self-Pay Pricing to $349 From $499
A 30% reduction on the manufacturer's direct channel, and part of a broader repricing that has reshaped the affordability argument.
SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Head
751 adults, 72 weeks, maximum tolerated doses of each — the only trial that has compared these two drugs directly for weight management.
Semaglutide Came Off the Shortage List in February 2025 — With a May Deadline for Outsourcing Facilities
The delisting closed the pathway that had permitted compounding at scale, on a defined wind-down timetable.
SUMMIT: Tirzepatide Cuts Worsening Heart-Failure Events by 38% in Obesity-Related HFpEF
A 731-patient phase 3 trial in a specific cardiac phenotype, with imaging substudies supporting a mechanical explanation.
Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabetes
The longest published follow-up in this field: 1,032 participants, 176 weeks of treatment, and a hard clinical endpoint rather than a surrogate.
The Tirzepatide Shortage Delisting Was Not One Date — It Was a Year of Litigation
Widely reported as 'October 2024', the delisting was determined, remanded, contested and re-affirmed across five months. We had it wrong too.
If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.
Categories this desk covers
FDA and regulation
1 published
Clinical trials
1 published
Manufacturer and product updates
1 published
Pricing and access
0 published
Pharmacy recalls and warning letters
0 published
Telehealth and policy
0 published
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Category | Primary source | What we will not do |
|---|---|---|
| FDA and regulation | The agency's own notice or guidance document | Report a summary as the rule |
| Clinical trials | Registry entry and peer-reviewed publication | Chart a topline figure as a result |
| Manufacturer updates | The company's own release, labelled as such | Rewrite a release as our conclusion |
| Pricing and access | The provider's published page, captured and dated | Repeat a discount claim unchecked |
| Recalls and warning letters | The published letter or recall notice | Imply wrongdoing beyond the document |
| Telehealth policy | Statute, board rule or agency action | Generalise one state to the country |
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Published | 0 | 0% |
| None yet | 1 | 100% |
- Build the news sitemap to include only items published in the last 48 hours, and rotate them out afterwards.
- NewsArticle structured data must match the visible headline, dates and author. No schema-only claims.
- Set a standing monitor on FDA compounding guidance, the 503B bulks list, warning letters and recall notices.
- Every story needs a named author and, where it makes a clinical statement, a medical reviewer.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide Provider ReviewsProviders
- Tirzepatide Provider Comparison ToolTools
- Tirzepatide Price Comparison by ProviderPillar / Money
- Tirzepatide Cost Without InsurancePillar / Money
- Shed Tirzepatide ReviewProviders
- Questions to Ask a GLP-1 ClinicianTools
- Privacy PolicyCore & Trust
GLP-1 Tirzepatide Review. “GLP-1 and Tirzepatide News.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/news/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.